Michael L Wetter

This inventor holds 17 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 7 EPO patents. Top assignees: Glaxosmithkline Biologicals Sa, Glycovaxyn Ag, Janssen Pharmaceuticals, Inc.. Active years: 2014-2025.

USPTO Granted Patents = 17 (Patent Applications = 4)

% Patents Active = 88.2

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 88(Granted Patents)

Location History:

Zürich, CH (2022)
Zurich, CH (2014 - 2024)

Company Filing History:

12 out of 545

Glaxosmithkline Biologicals Sa

Janssen Pharmaceuticals, Inc.

Limmatech Biologics Ag

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12214029 - Polysaccharide and uses thereof (2025-02-04),

2. 12076385 - Methods and compositions for immune protection against extra-intestinal pathogenic (2024-09-03),

3. 11944675 - Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells (2024-04-02),

4. 11738076 - Polysaccharide and uses thereof (2023-08-29),

5. 11484582 - Methods and compositions for immune protection against extra-intestinal pathogenic (2022-11-01),

6. 11236136 - Methods of producing glycosylated proteins (2022-02-01),

7. 10973901 - Production of recombinant vaccine inby enzymatic conjugation (2021-04-13),

8. 10940192 - Polysaccharide and uses thereof (2021-03-09),

9. 10835592 - Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells (2020-11-17),

10. 10583185 - Methods and compositions for immune protection against extra-intestinal pathogenic (2020-03-10),

11. 10441647 - Polysaccharide and uses thereof (2019-10-15),

12. 10307473 - Capsular gram-positive bacteria bioconjugate vaccines (2019-06-04),

13. 10195262 - [object Object] (2019-02-05),

14. 9700612 - Polysaccharide and uses thereof (2017-07-11),

15. 9585950 - Capsular gram-positive bacteria bioconjugate vaccines (2017-03-07),

Title: The Innovative Journey of Inventor Michael L Wetter

Introduction

Michael L Wetter is a distinguished inventor based in Zurich, Switzerland, known for his significant contributions to the field of biochemistry. With a remarkable portfolio of 17 patents, Wetter's work primarily focuses on polysaccharides and their applications, particularly in medical compositions and vaccines.

Latest Patents

Among his most recent patents is the development of a polysaccharide referred to as O25B. This innovation includes prokaryotic host cells containing enzymes, such as glycosyltransferases, leveraged for the production of O25B. Notably, this includes bioconjugates that incorporate O25B linked to carrier proteins, paving the way for new pharmaceutical compositions. These inventions are aimed at providing vaccines to counter infections caused by extra-intestinal pathogenic E. coli (ExPEC). Wetter has also focused on methods and compositions to induce immune responses against ExPEC, detailing the use of conjugates of polysaccharide antigens covalently bound to detoxified exotoxin carrier proteins.

Career Highlights

Michael L Wetter has had a noteworthy career collaborating with prominent companies in pharmaceuticals, including GlaxoSmithKline Biologicals SA and Glycovaxyn AG. His expertise and innovations have played a critical role in advancing vaccine development, particularly against diseases linked to pathogenic bacteria.

Collaborations

Throughout his career, Wetter has collaborated with several esteemed colleagues, including Michael T Kowarik and Manuela Mally. These partnerships have enabled him to leverage diverse expertise and drive forward the research and development of innovative solutions in his field.

Conclusion

Michael L Wetter's contributions to the field of biochemistry highlight the vital role of innovation in addressing public health challenges. With a focus on polysaccharides and their applications in vaccines, Wetter continues to advance scientific knowledge and improve methods for disease prevention through his extensive patent portfolio. His work exemplifies the spirit of invention and collaboration within the scientific community.